Zydus Lifesciences has received approval from the US Food and Drug Administration (USFDA) for its Pimavanserin capsules and tablets. The company’s new medication is intended to treat certain conditions and has passed regulatory requirements. Additionally, the company uses cookies for various purposes such as analytics and advertising. By continuing to use their site, users are agreeing to the use of cookies. For more information, users can refer to the company’s Cookie Policy and Cookie Settings.
Source link
Zydus Lifesciences secures USFDA nod for Pimavanserin capsules, tablets
